


Cytotoxic action of D-24851 against MDR
murine leukemic subline L1210/VCR



• In contrast to Taxol, doxorubicin, vincristine or epothilone B, D-24851 has the same cytotoxic activity against the MDR mouse leukemic subline L1210/VCR as against the normal

L1210

FIG. 1

Action of D-24851 on a multidrug-resistant tumor




FIG. 2


**Influence of D-24851 on the multidrug-resistant murine
leukemia L1210 (dose 10% of the LD₅₀)**

	Dose (mg/kg)	L1210	L1210/VCR
		ILS %	ILS %
D-24851	4 x 100 p.o.	46	42
	4 x 147 p.o.	94	85
Adriamycin	4 x 1 i.p.	158	6
Taxol	4 x 15 i.p.	82	6
Vincristine	4 x 0.2 i.p.	47	-11

FIG. 3


Cytotoxic activity of vincristine

on a human leukemia (LT12 and LT12/mdr)




Cytotoxic activity of adriamycin

(doxorubicin) on a human leukemia (LT12 and LT12/mdr)



Cytotoxic activity of Taxol

on a human leukemia (LT12 and LT12/mdr)



Cytotoxic activity of D-24851

on a human leukemia (LT12 and LT12/mdr)





FIG. 4

FIG. 5



- D-24851 inhibits the migration of MO4 cells in a dose-dependent manner
From this, an antiinvasive and an antimetastatic action can be derived for D-24851.

Neurotoxicity

	D-24851 10x 20 mg/kg p.o	Vincristine 10x 0.2 mg/kg i.p.	Taxol 10x 15 mg/kg i.p.
Ataxia (rat)	--	+	++
Traction (rat)	--	+	++
Reaction (rat)	--	++	+++

+ p ≥ 0.05 vs. control ++ p ≥ 0.01 vs. control -- = no effect

D-24851 shows no neurotoxicity [sic] in maximally antitumor-active doses in contrast to Taxol and vincristine

FIG. 6

Influence of D-24851 on the nerve conduction velocity (NCV) (rat)





FIG. 7

FIG. 8

Angiogenesis in human endothelial cell culture
Vital staining, 44 hours after induction of angiogenesis

DMSO control



0.1 μ M D24851





FIG. 9

Angiogenesis in human endothelial cell culture

Lethal staining, 22 hours after induction of angiogenesis

DMSO control



0.1 μ M D24851

